Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07HGR
|
|||
| Former ID |
DAP000587
|
|||
| Drug Name |
Lisinopril
|
|||
| Synonyms |
Acerbon; Acercomp; Alapril; Carace; Cipral; Cipril; Coric; Doneka; Hipril (TN); Inhibril; Inopril; LPR; Linopril; Linvas; Lipril; Lisinal; Lisinopril (INN); Lisinopril (anhydrous); Lisinopril anhydrous; Lisinoprilum; Lisinoprilum [Latin]; Lisipril; Lisoril; Lispril; Longes; Loril; Lysinopril; MK 521; MK 522; MK-521; Noperten; Novatec; Presiten; Prinil; Prinivil; Prinivil (TN); Sinopril; Sinopryl; Tensopril; Tensopril (TN); Tensyn; Tersif; Vivatec; Zestril; Zestril (TN)
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hypertension [ICD-11: BA00-BA04; ICD-9: 401] | Approved | [1], [2] | |
| Therapeutic Class |
Antihypertensive Agents
|
|||
| Company |
Merck & Co
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H31N3O5
|
|||
| Canonical SMILES |
C1CC(N(C1)C(=O)C(CCCCN)NC(CCC2=CC=CC=C2)C(=O)O)C(=O)O
|
|||
| InChI |
1S/C21H31N3O5/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29)/t16-,17-,18-/m0/s1
|
|||
| InChIKey |
RLAWWYSOJDYHDC-BZSNNMDCSA-N
|
|||
| CAS Number |
CAS 76547-98-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7888691, 7979780, 8149783, 10322439, 11336212, 11361451, 11363391, 11365953, 11368515, 11372101, 11374737, 11376677, 11462423, 11466329, 11467449, 11485087, 11486217, 11489272, 11490756, 11492854, 11494311, 11654003, 12013163, 14806092, 14830773, 25622282, 26612244, 26680616, 26697064, 39384398, 46504893, 47515403, 47515404, 47810844, 47885506, 47885507, 48035230, 49698425, 49835323, 50019882, 50085996, 50124344, 53787084, 56311259, 57362085, 78195378, 81066263, 85787499, 87560323, 92124278
|
|||
| ChEBI ID |
CHEBI:43755
|
|||
| ADReCS Drug ID | BADD_D01300 | |||
| SuperDrug ATC ID |
C09AA03
|
|||
| SuperDrug CAS ID |
cas=083915837
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Angiotensin-converting enzyme (ACE) | Target Info | Inhibitor | [3] |
| KEGG Pathway | Renin-angiotensin system | |||
| Chagas disease (American trypanosomiasis) | ||||
| Hypertrophic cardiomyopathy (HCM) | ||||
| Pathwhiz Pathway | Angiotensin Metabolism | |||
| Reactome | Metabolism of Angiotensinogen to Angiotensins | |||
| WikiPathways | ACE Inhibitor Pathway | |||
| Metabolism of Angiotensinogen to Angiotensins | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6360). | |||
| REF 2 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. | |||
| REF 3 | Involvement of vascular angiotensin II-forming enzymes in the progression of aortic abdominal aneurysms in angiotensin II- infused ApoE-deficient m... J Atheroscler Thromb. 2009 Jun;16(3):164-71. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.